Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation
|
Tweet
|
|
A procedure that sends targeted energy into the heart through a catheter can be used to treat a common type of irregular heartbeat, but little is known about the treatment’s long-term benefits and the best methods and circumstances for applying it, according to a new report funded by Department of Health & Human Services’s (HHS) Agency for Healthcare Research and Quality (AHRQ).
The report examines the use of a procedure called radiofrequency catheter ablation to treat a type of irregular heartbeat known as atrial fibrillation. The new comparative effectiveness report found that the procedure has been shown to provide benefits in maintaining normal heart rhythm over short periods of time (up to 1 year) but found little evidence indicating whether the procedure reduces the chance that patients will experience atrial fibrillation over the long term.
The report, which compared radiofrequency catheter ablation to medication-based therapy, also found that the effect of the procedure on stroke, a major risk for patients with atrial fibrillation, is unknown. Radiofrequency catheter ablation-a procedure in which a long, thin, flexible tube is put through a blood vessel into the heart-often is used when medications do not work. In this procedure, energy pulses are delivered through the catheter to the heart, destroying small areas of heart tissue where abnormal electrical signals may cause an arrhythmia to start.
Different techniques and instruments can be used for the procedure. While there is no strong evidence to suggest that one particular technique is best for any given patient, there is general consensus concerning a basic approach to ablation procedures for atrial fibrillation. In addition, there is little evidence indicating the procedure’s effectiveness when used as a first-line therapy instead of medication.
“Radiofrequency holds promise for treating atrial fibrillation, but it is clear that more research is needed to demonstrate its potential long-term benefits,” said AHRQ Director Carolyn M. Clancy, M.D. “This report crystallizes the questions that researchers need to ask going forward.”
Atrial fibrillation, the most common type of irregular heartbeat in adults, affects more than 2.2 million Americans, putting them at risk for heart failure, blood clots, or stroke. Patients with atrialfibrillation are typically treated with medication first, but medicines only work for about half of patients for preventing recurrence of atrial fibrillation.
The report calls for more research on the effect of radiofrequency catheter ablation on quality of life. In particular, more research is needed for groups of patients for whom the research is especially lacking, such as women, the elderly, and patients who have other conditions such as heart failure or High Blood Pressure.
Earlier this year, HHS’ Food and Drug Administration approved the first two ablation catheters indicated for use in treating atrial fibrillation, in the United States. However, physicians often use other catheters that have not been approved by the FDA for atrial fibrillation. The FDA also found that there is no conclusive evidence that people whose symptoms are reduced with ablation are less likely to have a stroke. Therefore, the FDA explicitly endorsed existing clinical guidelines that recommend that patients at risk for stroke continue to take preventive blood-thinning medications after radiofrequency catheter ablation.
As a condition of catheter approvals, the FDA mandated that the catheters’ manufacturer must conduct two post approval studies (PAS) to collect long term safety data. The mandated studies apply only to FDA-approved catheters, and not to devices used off-label in clinical practice. The first PAS is a post approval registry, which will collect safety (adverse event) data and operator experience information through 7 days post-treatment with the approved ablation catheters. The study will also collect data on long term safety (adverse events) data, such as death, stroke, myocardial infarction, clinically manifested pulmonary vein stenosis, etc., at 5 years post-treatment. The second PAS is a subgroup analysis from an ongoing larger study that will look at the incidence of stroke, and compare the 3-year incidence of stroke between patients treated with the approved ablation catheters versus patients treated with medication. This study will analyze total mortality, serious bleeding and cardiac arrest.
Also, last week, the FDA approved a new medication, dronedarone, for treatment of atrial fibrillation.
AHRQ’s new report, Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation, is the newest analysis from the Agency’s Effective Health Care program. That program, authorized by the Medicare Prescription Drug, Improvement, and Modernization Act, represents an important federal effort to compare alternative treatments for health conditions and make the findings public. The program is intended to help patients, doctors, nurses, and others choose the most effective treatments
Source: Agency for Healthcare Research and Quality (AHRQ)
 |
 |
 |
 | ||
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
